论文部分内容阅读
目的:观察并探讨同步放化疗治疗不可手术的Ⅲ期非小细胞肺癌的临床疗效及副反应。方法:64例III期非小细胞肺癌病例随机分成两组,同步放化疗组34例(治疗组)和单纯放疗组30例(对照组),放疗均采用三维适形放疗,单次剂量为2GY,5次/周,共6-7周,总剂量为60-70GY;治疗组于放疗开始第一天行DP方案化疗2-3周期,21d为1个周期。结果:治疗组的总有效率及疾病控制率均优于对照组,差异有统计学意义(P<0.05);两组毒副反应主要表现为骨髓抑制、放射性肺炎和放射性食管炎等,治疗组副反应发生率虽比对照组稍高,但差异无统计学意义(P>0.05)。结论:同步放化疗对Ⅲ期非小细胞肺癌有明显的近期疗效,可延长生存期、改善生活质量,相应的毒副反应患者可以耐受。
Objective: To observe and discuss the clinical efficacy and side effects of concurrent chemoradiotherapy in the treatment of inoperable stage Ⅲ non-small cell lung cancer. Methods: Sixty-four patients with stage III non-small cell lung cancer were randomly divided into two groups: 34 patients in the concurrent chemoradiation group and 30 patients in the radiotherapy group. The radiotherapy was performed by three-dimensional conformal radiotherapy. The single dose was 2GY , 5 times / week, a total of 6-7 weeks, a total dose of 60-70GY; the treatment group in the first day of radiotherapy line chemotherapy DP 2-3 cycles, 21d for a cycle. Results: The total effective rate and disease control rate in the treatment group were better than those in the control group (P <0.05). The side effects of the two groups were mainly myelosuppression, radiation pneumonitis and radiation esophagitis. The treatment group Although the incidence of side effects slightly higher than the control group, but no significant difference (P> 0.05). Conclusions: Concurrent chemoradiation has obvious curative effect on stage Ⅲ non-small cell lung cancer, which can prolong survival and improve quality of life. Patients with corresponding toxicities can tolerate it.